# Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

> **NCT01042704** · PHASE1 · COMPLETED · sponsor: **Robert Redner, MD** · enrollment: 29 (actual)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Aspirin
- **DRUG:** Prophylaxis
- **DRUG:** Antibiotic
- **OTHER:** Biweekly Follow Up
- **OTHER:** Cyclical Follow Up
- **OTHER:** Restaging
- **OTHER:** Post-Treatment Follow Up

## Key facts

- **NCT ID:** NCT01042704
- **Lead sponsor:** Robert Redner, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-01
- **Final completion:** 2015-03
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01042704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01042704, "Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01042704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*